Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

February 15, 2019

European Commission Approves Adcetris/Chemo Combo for Some Hodgkin’s

News

The European Commission has approved the used of Adcetris (brentuximab vedotin) in combination with standard chemotherapy for the initial treatment of advanced CD30-positive Hodgkin’s lymphoma patients in the European Union, Norway, Liechtenstein and Iceland. The ... Read more

February 11, 2019

Rituxan Plus Chemo Fails to Benefit Newly Diagnosed Primary CNS Lymphoma Patients in Clinical Trial

News

Adding Rituxan (rituximab) to standard first-line chemotherapy did not improve disease outcomes for people with primary central nervous system (CNS) lymphoma in a Phase 3 clinical trial, results show. ... Read more

January 22, 2019

Childhood Hodgkin’s Lymphoma Survivors At Higher Risk for Cancer Later in Life, Study Shows

News

Survivors of childhood Hodgkin’s lymphoma are 14 times more likely to develop a subsequent solid tumor than the general population, and this risk remains high for several decades post-diagnosis, ... Read more

January 21, 2019

LOXO-305 Trial Begins for Lymphoma, Leukemia Patients Resistant to BTK Inhibitors

News

A Phase 1/2 trial is evaluating Loxo Oncology‘s BTK inhibitor LOXO-305 in leukemia and lymphoma patients who failed, or were intolerant to, approved BTK inhibitors. The trial, so far being ... Read more

January 3, 2019

Phase 3 Trial Testing Biosimilar to Rituxan, JHL1101, in DLBCL Patients Begins

News

Patient dosing has begun in a Phase 3 trial comparing JHL Biotech‘s proposed biosimilar of rituximab JHL1101 to the original medicine, Rituxan (rituximab), in diffuse large B-cell lymphoma (DLBCL), the company announced. ... Read more

December 18, 2018

Depleting White Blood Cells Improves Response to CAR T-cell Therapy in Heavily Treated Patients, Trial Shows

News

A preconditioning chemotherapy regimen given before CD30.CAR-T therapy — a CAR T-cell therapy directed at CD30-positive cancers — seems to improve heavily treated lymphoma patients’ responses to the treatment, a Phase ... Read more

December 17, 2018

Calquence Shows Durable Responses in Relapsed or Refractory Mantle Cell Lymphoma, Phase 2 Trial Shows

News

Calquence (acalabrutinib), a treatment for mantle cell lymphoma (MCL) patients who have failed at least one prior therapy, reduced tumor burden in four of five patients in a Phase 2 ... Read more

December 14, 2018

Truxima Shows Safety, Efficacy Comparable to Rituxan in Advanced Follicular Lymphoma

News

Truxima (rituximab-abbs), a biosimilar to Rituxan (rituxumab), has similar safety and efficacy as the original product in patients with advanced follicular lymphoma after two years, results from a Phase ... Read more

December 12, 2018

Follow-up Trial Results Reinforce Yescarta as Relapsed Non-Hodgkin’s Lymphoma Therapy

News

More than two years after receiving treatment with Yescarta (axicabtagene ciloleucel), 51% of non-Hodgkin’s lymphoma patients included in the ZUMA-1 Phase 1/2 clinical trial are still alive, and 39% ... Read more

December 5, 2018

5F9-Rituxan Combo Eliminates Tumors in One-third of DLBCL, Follicular Lymphoma Patients

News

A combination of Forty Seven‘s macrophage checkpoint inhibitor Hu5F9-G4 and Rituxan (rituximab) is safe and completely eliminated tumors in one-third of non-Hodgkin’s lymphoma patients included in a Phase 1b trial. The ... Read more

Pin It on Pinterest